Dr. Cheng is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
333 Cottman Ave
Fox Chase Cancer Center
Philadelphia, PA 19111Phone+1 215-728-6900Fax+1 215-728-3639
Education & Training
Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 1998 - 1999
University at BuffaloFellowship, Hematology and Medical Oncology, 1996 - 1998
University of MinnesotaResidency, Internal Medicine, 1992 - 1995- University of Minnesota Medical SchoolClass of 1992
Certifications & Licensure
PA State Medical License 1998 - 2024
MN State Medical License 1994 - 1997- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer Start of enrollment: 2000 May 01
- Studying Fibroblast Activity in Patients With Localized Pancreatic Cancer Undergoing Surgery Start of enrollment: 2007 Aug 01
Publications & Presentations
PubMed
- 185 citationsPhase II trial of single agent Val-boroPro (talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancerKalyani Narra, Stefanie R. Mullins, Hyung Ok Lee, Brenda Strzemkowski-Brun, Kimberly Magalong
Cancer Biology & Therapy. 2007-11-01 - 142 citationsSelective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold.Koen Jansen, Leen Heirbaut, Jonathan D. Cheng, Jurgen Joossens, Oxana Ryabtsova
ACS Medicinal Chemistry Letters. 2013-03-25 - 156 citationsExtended Structure–Activity Relationship and Pharmacokinetic Investigation of (4-Quinolinoyl)glycyl-2-cyanopyrrolidine Inhibitors of Fibroblast Activation Protein (FAP)Koen Jansen, Leen Heirbaut, Robert Verkerk, Jonathan D. Cheng, Jurgen Joossens
Journal of Medicinal Chemistry. 2014-03-24
Journal Articles
- Pan-Tumor Genomic Biomarkers for PD-1 Checkpoint Blockade–Based ImmunotherapyJonathan Cheng, Patrick A Ott, Elizabeth R Plimack, Antoni Ribas, Andrew Joe, Science Magazine
Press Mentions
According to New Multinational Survey, Healthcare Providers Believe Immunotherapy Has Potential to Positively Impact Earlier-Stage Cancer Treatment Landscape Across Tumor TypesSeptember 13th, 2021- MiR Scientific Snags BMS Melanoma, Genitourinary Commercial Leader for Cancer Detection TestAugust 13th, 2021
- Bristol Myers, Yielding to FDA Pressure, Pulls Opdivo in Post-Nexavar Liver CancerJuly 26th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
